Acrivon Therapeutics Inc Corporate R&D Event Transcript
Good morning, everyone, and welcome to today's conference call. My name is Adam Levy, and I'm Chief Financial Officer and Head of Investor Relations at Acrivon Therapeutics. This morning, we are going to share some exciting clinical data and provide other updates across our pipeline programs.
Next slide, please. Before we begin, I'd like to remind you that certain statements made during this call may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21(e) of the Securities Exchange Act of 1934 as amended. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. For a discussion of these and other important risk factors, please refer to the Risk Factors section of our most recent annual report on Form 10-K,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
